joint arthroplasty
Conditions
Interventions
rivaroxaban group:administered rivaroxaban 10mg,qd,po
Sponsors
Drum Tower Hospital Affiliated to Medical School of Nanjing University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) alduts; (2) selective operation of total joint arthroplasty,unicompartmental knee arthroplasty, hemiarthroplasty, revision total joint arthroplasty; (3) administered with rivaroxaban after the operation.
Exclusion criteria
Exclusion criteria: (1) allergic to rivaroxaban or any pharmaceutical excipients in the tablets; (2) active bleeding; (3) high risk of major bleeding; (4) liver disease with disturbance of coagulation including Child Pugh B and C hepatocirrhosis; (5) pregnant and lactating women; (6) combined administration with drugs that affect rivaroxaban metabolism; (7) can not or do not want to cooperate with the study; (8) premature withdrawl of rivaroxaban.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma concentration of rivaroxaban;VTE event;polymorphism;APTT;PT; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum creatine;drainage volume after the operation;bleeding events; | — |
Countries
China
Contacts
Public ContactQing Jiang
Drum Tower Hospital Affiliated to Medical School of Nanjing University
Outcome results
None listed